Abstract
Aims: Exposure to high altitude (HA) hypoxia decreases exercise performance in healthy subjects. Although β-blockers are known to affect exercise capacity in normoxia, no data are available comparing selective and nonselective β-adrenergic blockade on exercise performance in healthy subjects acutely exposed to HA hypoxia. We compared the impact of nebivolol and carvedilol on exercise capacity in healthy subjects acutely exposed to HA hypobaric hypoxia. Methods: In this double-blind, placebo-controlled trial, 27 healthy untrained sea-level (SL) residents (15 males, age 38.3 ± 12.8 years) were randomized to placebo (n = 9), carvedilol 25 mg b.i.d. (n = 9), or nebivolol 5 mg o.d. (n = 9). Primary endpoints were measures of exercise performance evaluated by cardiopulmonary exercise testing at sea level without treatment, and after at least 3 weeks of treatment, both at SL and shortly after arrival at HA (4559 m). Results: HA hypoxia significantly decreased resting and peak oxygen saturation, peak workload, VO 2, and heart rate (HR) (P <0.01). Changes from SL (no treatment) differed among treatments: (1) peak VO 2 was better preserved with nebivolol (-22.5%) than with carvedilol (-37.6%) (P <0.01); (2) peak HR decreased with carvedilol (-43.9 ± 11.9 beats/min) more than with nebivolol (-24.8 ± 13.6 beats/min) (P <0.05); (3) peak minute ventilation (VE) decreased with carvedilol (-9.3%) and increased with nebivolol (+15.2%) (P= 0.053). Only peak VE changes independently predicted changes in peak VO 2 at multivariate analysis (R= 0.62, P <0.01). Conclusions: Exercise performance is better preserved with nebivolol than with carvedilol under acute exposure to HA hypoxia in healthy subjects.
| Original language | English |
|---|---|
| Pages (from-to) | 240-248 |
| Number of pages | 9 |
| Journal | Cardiovascular Therapeutics |
| Volume | 30 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2012 |
Fingerprint
Keywords
- Adrenergic receptor blockade
- Autonomic nervous system
- Beta receptor
- Cardiopulmonary exercise test
- Carvedilol
- Clinica trial
- Hypoxia
- Nebivolol
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
- Pharmacology
Cite this
Effects of Beta-Blockade on Exercise Performance at High Altitude : A Randomized, Placebo-Controlled Trial Comparing the Efficacy of Nebivolol versus Carvedilol in Healthy Subjects. / Valentini, Mariaconsuelo; Revera, Miriam; Bilo, Grzegorz; Caldara, Gianluca; Savia, Giulio; Styczkiewicz, Katarzyna; Parati, Sara; Gregorini, Francesca; Faini, Andrea; Branzi, Giovanna; Malfatto, Gabriella; Magrì, Damiano; Agostoni, Piergiuseppe; Parati, Gianfranco.
In: Cardiovascular Therapeutics, Vol. 30, No. 4, 08.2012, p. 240-248.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of Beta-Blockade on Exercise Performance at High Altitude
T2 - A Randomized, Placebo-Controlled Trial Comparing the Efficacy of Nebivolol versus Carvedilol in Healthy Subjects
AU - Valentini, Mariaconsuelo
AU - Revera, Miriam
AU - Bilo, Grzegorz
AU - Caldara, Gianluca
AU - Savia, Giulio
AU - Styczkiewicz, Katarzyna
AU - Parati, Sara
AU - Gregorini, Francesca
AU - Faini, Andrea
AU - Branzi, Giovanna
AU - Malfatto, Gabriella
AU - Magrì, Damiano
AU - Agostoni, Piergiuseppe
AU - Parati, Gianfranco
PY - 2012/8
Y1 - 2012/8
N2 - Aims: Exposure to high altitude (HA) hypoxia decreases exercise performance in healthy subjects. Although β-blockers are known to affect exercise capacity in normoxia, no data are available comparing selective and nonselective β-adrenergic blockade on exercise performance in healthy subjects acutely exposed to HA hypoxia. We compared the impact of nebivolol and carvedilol on exercise capacity in healthy subjects acutely exposed to HA hypobaric hypoxia. Methods: In this double-blind, placebo-controlled trial, 27 healthy untrained sea-level (SL) residents (15 males, age 38.3 ± 12.8 years) were randomized to placebo (n = 9), carvedilol 25 mg b.i.d. (n = 9), or nebivolol 5 mg o.d. (n = 9). Primary endpoints were measures of exercise performance evaluated by cardiopulmonary exercise testing at sea level without treatment, and after at least 3 weeks of treatment, both at SL and shortly after arrival at HA (4559 m). Results: HA hypoxia significantly decreased resting and peak oxygen saturation, peak workload, VO 2, and heart rate (HR) (P <0.01). Changes from SL (no treatment) differed among treatments: (1) peak VO 2 was better preserved with nebivolol (-22.5%) than with carvedilol (-37.6%) (P <0.01); (2) peak HR decreased with carvedilol (-43.9 ± 11.9 beats/min) more than with nebivolol (-24.8 ± 13.6 beats/min) (P <0.05); (3) peak minute ventilation (VE) decreased with carvedilol (-9.3%) and increased with nebivolol (+15.2%) (P= 0.053). Only peak VE changes independently predicted changes in peak VO 2 at multivariate analysis (R= 0.62, P <0.01). Conclusions: Exercise performance is better preserved with nebivolol than with carvedilol under acute exposure to HA hypoxia in healthy subjects.
AB - Aims: Exposure to high altitude (HA) hypoxia decreases exercise performance in healthy subjects. Although β-blockers are known to affect exercise capacity in normoxia, no data are available comparing selective and nonselective β-adrenergic blockade on exercise performance in healthy subjects acutely exposed to HA hypoxia. We compared the impact of nebivolol and carvedilol on exercise capacity in healthy subjects acutely exposed to HA hypobaric hypoxia. Methods: In this double-blind, placebo-controlled trial, 27 healthy untrained sea-level (SL) residents (15 males, age 38.3 ± 12.8 years) were randomized to placebo (n = 9), carvedilol 25 mg b.i.d. (n = 9), or nebivolol 5 mg o.d. (n = 9). Primary endpoints were measures of exercise performance evaluated by cardiopulmonary exercise testing at sea level without treatment, and after at least 3 weeks of treatment, both at SL and shortly after arrival at HA (4559 m). Results: HA hypoxia significantly decreased resting and peak oxygen saturation, peak workload, VO 2, and heart rate (HR) (P <0.01). Changes from SL (no treatment) differed among treatments: (1) peak VO 2 was better preserved with nebivolol (-22.5%) than with carvedilol (-37.6%) (P <0.01); (2) peak HR decreased with carvedilol (-43.9 ± 11.9 beats/min) more than with nebivolol (-24.8 ± 13.6 beats/min) (P <0.05); (3) peak minute ventilation (VE) decreased with carvedilol (-9.3%) and increased with nebivolol (+15.2%) (P= 0.053). Only peak VE changes independently predicted changes in peak VO 2 at multivariate analysis (R= 0.62, P <0.01). Conclusions: Exercise performance is better preserved with nebivolol than with carvedilol under acute exposure to HA hypoxia in healthy subjects.
KW - Adrenergic receptor blockade
KW - Autonomic nervous system
KW - Beta receptor
KW - Cardiopulmonary exercise test
KW - Carvedilol
KW - Clinica trial
KW - Hypoxia
KW - Nebivolol
UR - http://www.scopus.com/inward/record.url?scp=84863484129&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863484129&partnerID=8YFLogxK
U2 - 10.1111/j.1755-5922.2011.00261.x
DO - 10.1111/j.1755-5922.2011.00261.x
M3 - Article
C2 - 21883997
AN - SCOPUS:84863484129
VL - 30
SP - 240
EP - 248
JO - Cardiovascular Therapeutics
JF - Cardiovascular Therapeutics
SN - 1755-5914
IS - 4
ER -